TY - JOUR
T1 - Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
AU - NASH CLINICAL RESEARCH NETWORK
AU - Allende, Daniela S.
AU - Gawrieh, Samer
AU - Cummings, Oscar W.
AU - Belt, Patricia
AU - Wilson, Laura
AU - Van Natta, Mark
AU - Behling, Cynthia A.
AU - Carpenter, Danielle
AU - Gill, Ryan M.
AU - Kleiner, David E.
AU - Yeh, Mathew M.
AU - Chalasani, Naga
AU - Guy, Cynthia D.
AU - Garner, Donna
AU - Hertel, Paula
AU - Himes, Ryan
AU - Lawson, Alicia
AU - Miloh, Tamir
AU - Triggs, Nicole
AU - Bramlage, Kristin
AU - Carr, April
AU - Cecil, Kim
AU - McNeill, Meghan
AU - Mouzaki, Marialena
AU - Trout, Andrew
AU - Xanthakos, Stavra
AU - Bernstein, Kimberlee
AU - DeVore, Stephanie
AU - Kohli, Rohit
AU - Lake, Kathleen
AU - Podberesky, Daniel
AU - Towbin, Alex
AU - Allende, Daniela
AU - Bellar, Annette
AU - Dasarathy, Jaividhya
AU - Dasarathy, Srinivasan
AU - McCullough, Arthur J.
AU - Penumatsa, Revathi
AU - Reen, Jaspreet S.
AU - Lavine, Joel E.
AU - Mencin, Ali
AU - Reynoso, Elena
AU - Abdelmalek, Manal F.
AU - Bashir, Mustafa
AU - Buie, Stephanie
AU - Diehl, Anna Mae
AU - Guy, Cynthia
AU - Kigongo, Christopher
AU - Kopping, Mariko
AU - Barlow, Sarah
N1 - Funding Information:
The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (grants U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, U01DK061713). Additional support is received from the National Center for Advancing Translational Sciences (NCATS) (grants UL1TR000439, UL1TR000077, UL1TR000436, UL1TR000150, UL1TR000424, UL1TR000006, UL1TR000448, UL1TR000040, UL1TR000100, UL1TR000004, UL1TR000423, UL1TR000058, and UL1TR000454). This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute 2
Publisher Copyright:
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
PY - 2020
Y1 - 2020
N2 - Background/Aims: Glycogen synthesis and storage are normal hepatocyte functions. However, glycogenosis, defined as excess hepatocyte glycogen visible by routine H&E light microscopy, has not been well characterized in nonalcoholic fatty liver disease (NAFLD). Methods: Glycogenosis in NAFLD liver biopsies was graded as “none”, “focal” (in <50% of hepatocytes), or “diffuse” (in ≥50% of hepatocytes). Clinical and pathological variables associated with glycogenosis were assessed. 2047 liver biopsies were prospectively analysed. Results: In adults and children, any glycogenosis was present in 54% of cases; diffuse glycogenosis was noted in approximately 1/3 of cases. On multiple logistic regression analysis, adults with glycogenosis tended to be older (P =.003), female (P =.04), have higher serum glucose (P =.01), and use insulin (P =.02). Adults tended to have lower steatosis scores (P =.006) and lower fibrosis stages (P =.005); however, unexpectedly, they also tended to have more hepatocyte injury including ballooning (P =.003). On multiple logistic regression analysis, paediatric patients with glycogenosis were more likely to be Hispanic (P =.03), have lower body weight (P =.002), elevated triglycerides (P =.001), and a higher fasting glucose (P =.007). Paediatric patients with glycogenosis also had less steatosis (P <.001) than those without. Conclusions: Glycogenosis is common in adult and paediatric NAFLD, and is associated with clinical features of insulin resistance. Glycogenosis is important to recognize histologically because it may be misinterpreted as ballooning, and when diffuse, confusion with glycogen storage disorders or glycogenic hepatopathy must be avoided. The newly observed dichotomous relationship between glycogenosis and increased liver cell injury but decreased steatosis and fibrosis requires further study.
AB - Background/Aims: Glycogen synthesis and storage are normal hepatocyte functions. However, glycogenosis, defined as excess hepatocyte glycogen visible by routine H&E light microscopy, has not been well characterized in nonalcoholic fatty liver disease (NAFLD). Methods: Glycogenosis in NAFLD liver biopsies was graded as “none”, “focal” (in <50% of hepatocytes), or “diffuse” (in ≥50% of hepatocytes). Clinical and pathological variables associated with glycogenosis were assessed. 2047 liver biopsies were prospectively analysed. Results: In adults and children, any glycogenosis was present in 54% of cases; diffuse glycogenosis was noted in approximately 1/3 of cases. On multiple logistic regression analysis, adults with glycogenosis tended to be older (P =.003), female (P =.04), have higher serum glucose (P =.01), and use insulin (P =.02). Adults tended to have lower steatosis scores (P =.006) and lower fibrosis stages (P =.005); however, unexpectedly, they also tended to have more hepatocyte injury including ballooning (P =.003). On multiple logistic regression analysis, paediatric patients with glycogenosis were more likely to be Hispanic (P =.03), have lower body weight (P =.002), elevated triglycerides (P =.001), and a higher fasting glucose (P =.007). Paediatric patients with glycogenosis also had less steatosis (P <.001) than those without. Conclusions: Glycogenosis is common in adult and paediatric NAFLD, and is associated with clinical features of insulin resistance. Glycogenosis is important to recognize histologically because it may be misinterpreted as ballooning, and when diffuse, confusion with glycogen storage disorders or glycogenic hepatopathy must be avoided. The newly observed dichotomous relationship between glycogenosis and increased liver cell injury but decreased steatosis and fibrosis requires further study.
KW - adults
KW - children
KW - hepatic glycogen
KW - pathology
KW - steatohepatitis
UR - http://www.scopus.com/inward/record.url?scp=85105688994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105688994&partnerID=8YFLogxK
U2 - 10.1111/liv.14773
DO - 10.1111/liv.14773
M3 - Article
C2 - 33354866
AN - SCOPUS:85105688994
JO - Liver International
JF - Liver International
SN - 1478-3223
ER -